Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of LNK01001 (zepusertinib) capsules in adults with moderate-to-severe atopic dermatitis
CTR20234306Phase 3Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zemprocitinib in atopic dermatitis (AD), sponsored by Lynk Pharmaceuticals. Started Feb 2024; status: completed.
02
Drugs
zemprocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20234306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234306.